Cancer Center, Taipei Veterans General Hospital, Taipei, Taiwan.
Int J Radiat Oncol Biol Phys. 2010 Jul 15;77(4):980-7. doi: 10.1016/j.ijrobp.2009.06.035. Epub 2009 Oct 26.
To review the effectiveness of reduced-dose and restricted-volume radiation-only therapy in the treatment of intracranial germinoma and to assess the feasibility of reducing or eliminating the use of chemotherapy.
Between January 1996 and March 2007, a retrospective analysis was performed that included 38 patients who received either reduced radiation alone (30 Gy for 26 patients) or reduced radiation with chemotherapy (n = 12 patients). All 38 patients received extended focal (including whole-ventricle) irradiation and were followed up until February 2008. Overall survival (OS) and relapse-free survival (RFS) rates were calculated. Variables associated with survival were evaluated by univariate Cox proportional hazards regression.
Median follow-up was 62.4 months (range, 10.1-142.5 months). The total 5-year OS rate was 93.7%. The 5-year OS and RFS rates for patients receiving radiation only were 100% and 96.2%, respectively. The rates for those receiving radiation plus chemotherapy were 83.3 % and 91.7%, respectively (not statistically significant). No predictive factor was significantly associated with the OS or RFS rate. Chemotherapy had no significant effect on survival but was associated with a higher incidence of treatment-related toxicity.
A further decrease in the radiation dose to 30 Gy with whole-ventricle irradiation is sufficient to treat selected patients with intracranial germinoma. Wide-field irradiation or chemotherapy should be avoided as these methods are unnecessary. Thus, reduction of the radiation dose to 30 Gy may be feasible, even without chemotherapy.
回顾单纯放疗在颅内生殖细胞瘤治疗中的有效性,并评估减少或消除化疗使用的可行性。
1996 年 1 月至 2007 年 3 月,进行了一项回顾性分析,纳入 38 例接受单纯放疗(26 例患者 30Gy)或放化疗(n=12 例)的患者。所有 38 例患者均接受扩展局部(包括全脑室)照射,并随访至 2008 年 2 月。计算总生存率(OS)和无复发生存率(RFS)。采用单因素 Cox 比例风险回归分析评估与生存相关的变量。
中位随访时间为 62.4 个月(范围 10.1-142.5 个月)。总 5 年 OS 率为 93.7%。单纯放疗组的 5 年 OS 和 RFS 率分别为 100%和 96.2%,放疗加化疗组分别为 83.3%和 91.7%(无统计学差异)。无预测因素与 OS 或 RFS 率显著相关。化疗对生存无显著影响,但与更高的治疗相关毒性发生率相关。
对于选择的颅内生殖细胞瘤患者,全脑室照射的放疗剂量进一步降至 30Gy 即可满足治疗需要。应避免广泛照射或化疗,因为这些方法是不必要的。因此,即使不进行化疗,也可能可行地降低放疗剂量至 30Gy。